glp-1 agonists marketing strategies 2025 Receptor Agonist Market Size GLP-1 Receptor Agonist Market Size
Description
Dong YH, Wu JH, Chang CH, Lin JW, Wu LC, Toh S
Both classes lower blood glucose, promote weight loss, and reduce cardiovascular risk, but SGLT2 inhibitors have stronger evidence for kidney and heart failure protection and are generally preferred in those conditions
May 4, 2026: Next-Gen GLP-1 Leads to 16% More Weight Loss
This is the most serious warning from the Food and Drug Administration (FDA)
If so, the two types of heart failure may be very similar, except that the cause of heart failure with a preserved ejection fraction may not be the same as that with a reduced ejection fraction
